tiprankstipranks
Hims & Hers Health, Inc. (DE:82W)
NYSE:82W
Germany Market

Hims & Hers Health (82W) Stock Forecast & Price Target

37 Followers
See the Price Targets and Ratings of:

82W Analyst Ratings

Moderate Buy
13Ratings
Moderate Buy
4 Buy
9 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Hims
& Hers Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

82W Stock 12 Month Forecast

Average Price Target

€23.75
▼(-3.76% Downside)
Based on 13 Wall Street analysts offering 12 month price targets for Hims & Hers Health in the last 3 months. The average price target is €23.75 with a high forecast of €30.33 and a low forecast of €18.20. The average price target represents a -3.76% change from the last price of €24.68.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"€13","56":"€56","23.75":"€23.8","34.5":"€34.5","45.25":"€45.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.3299465,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€30.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.75189316818182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€23.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.1979679,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€18.20</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,23.75,34.5,45.25,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.26,24.726918961538463,25.193837923076924,25.660756884615385,26.127675846153846,26.594594807692307,27.06151376923077,27.528432730769232,27.995351692307693,28.462270653846154,28.929189615384615,29.396108576923076,29.863027538461537,{"y":30.3299465,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.26,24.22091485909091,24.18182971818182,24.14274457727273,24.10365943636364,24.06457429545455,24.025489154545458,23.986404013636363,23.947318872727273,23.908233731818182,23.86914859090909,23.83006345,23.79097830909091,{"y":23.75189316818182,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.26,23.79368983846154,23.327379676923076,22.861069515384617,22.394759353846155,21.928449192307692,21.46213903076923,20.99582886923077,20.529518707692308,20.063208546153845,19.596898384615383,19.13058822307692,18.66427806153846,{"y":18.1979679,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":50.9,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":39.95,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":55.28,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.56,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":48.04,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":41.15,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":33.16,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":29,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":23.1,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.435,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.94,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.26,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€30.33Average Price Target€23.75Lowest Price Target€18.20
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on DE:82W
Truist Financial
Truist Financial
Hold
Reiterated
06/09/26
Analysts Conflicted on These Healthcare Names: Gilead Sciences (NASDAQ: GILD), Hims & Hers Health (NYSE: HIMS) and Nurix Therapeutics (NASDAQ: NRIX)
Canaccord Genuity Analyst forecast on DE:82W
Canaccord Genuity
Canaccord Genuity
€27.73
Buy
12.36%
Upside
Reiterated
06/02/26
Hims & Hers Reaffirmed at Buy as Analyst Sees Peptide Upside, Keeps $32 Price Target Unchanged
Bank of America Securities Analyst forecast on DE:82W
Bank of America Securities
Bank of America Securities
€24.26€21.66
Hold
-12.22%
Downside
Reiterated
05/28/26
Hims & Hers price target lowered to $25 from $28 at BofAHims & Hers price target lowered to $25 from $28 at BofA
Barclays
€25.13
Buy
1.83%
Upside
Reiterated
05/20/26
Analysts' Top Healthcare Picks: Hims & Hers Health (HIMS), SAB Biotherapeutics (SABS)
Evercore ISI Analyst forecast on DE:82W
Evercore ISI
Evercore ISI
€20.8
Hold
-15.73%
Downside
Reiterated
05/12/26
Evercore ISI Sticks to Its Hold Rating for Hims & Hers Health (HIMS)
Jefferies
€22.1€21.23
Hold
-13.98%
Downside
Reiterated
05/12/26
Hims & Hers price target lowered to $24.50 from $25.50 at JefferiesHims & Hers price target lowered to $24.50 from $25.50 at Jefferies
Morgan Stanley Analyst forecast on DE:82W
Morgan Stanley
Morgan Stanley
€18.2
Hold
-26.26%
Downside
Assigned
05/12/26
Hims & Hers Health: Hold Maintained as Profitability Pressures Offset Growth; $21 Price Target Reiterated
TD Cowen Analyst forecast on DE:82W
TD Cowen
TD Cowen
€19.93€21.66
Hold
-12.22%
Downside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Harrow Health (NASDAQ: HROW), Hims & Hers Health (NYSE: HIMS) and ArriVent BioPharma, Inc. (NASDAQ: AVBP)
Citi
€20.8€24.26
Hold
-1.69%
Downside
Assigned
05/12/26
Hims & Hers price target raised to $28 from $24 at CitiHims & Hers price target raised to $28 from $24 at Citi
J.P. Morgan Analyst forecast on DE:82W
J.P. Morgan
J.P. Morgan
€30.33€28.6
Buy
15.87%
Upside
Reiterated
05/12/26
Hims & Hers price target lowered to $33 from $35 at JPMorganHims & Hers price target lowered to $33 from $35 at JPMorgan
Needham
€30.33
Buy
22.89%
Upside
Reiterated
05/12/26
Analyst Reaffirms Buy on Hims & Hers, Lifts Price Target to $35 on Long-Term Growth from Novo Partnership
Deutsche Bank  Analyst forecast on DE:82W
Deutsche Bank
Deutsche Bank
€24.26€21.66
Hold
-12.22%
Downside
Assigned
05/05/26
Hims & Hers price target lowered to $25 from $28 at Deutsche BankHims & Hers price target lowered to $25 from $28 at Deutsche Bank
Leerink Partners Analyst forecast on DE:82W
Leerink Partners
Leerink Partners
Hold
Reiterated
04/16/26
Push to ease peptide restrictions positive for Hims & Hers, says Leerink Push to ease peptide restrictions positive for Hims & Hers, says Leerink
Nephron Analyst forecast on DE:82W
Unknown Analyst
Nephron
Not Ranked
Nephron
€30.33
Buy
22.89%
Upside
Upgraded
03/09/26
Hims & Hers upgraded to Buy from Hold at Nephron ResearchHims & Hers upgraded to Buy from Hold at Nephron Research
BTIG
Hold
Reiterated
03/05/26
Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on DE:82W
Truist Financial
Truist Financial
Hold
Reiterated
06/09/26
Analysts Conflicted on These Healthcare Names: Gilead Sciences (NASDAQ: GILD), Hims & Hers Health (NYSE: HIMS) and Nurix Therapeutics (NASDAQ: NRIX)
Canaccord Genuity Analyst forecast on DE:82W
Canaccord Genuity
Canaccord Genuity
€27.73
Buy
12.36%
Upside
Reiterated
06/02/26
Hims & Hers Reaffirmed at Buy as Analyst Sees Peptide Upside, Keeps $32 Price Target Unchanged
Bank of America Securities Analyst forecast on DE:82W
Bank of America Securities
Bank of America Securities
€24.26€21.66
Hold
-12.22%
Downside
Reiterated
05/28/26
Hims & Hers price target lowered to $25 from $28 at BofAHims & Hers price target lowered to $25 from $28 at BofA
Barclays
€25.13
Buy
1.83%
Upside
Reiterated
05/20/26
Analysts' Top Healthcare Picks: Hims & Hers Health (HIMS), SAB Biotherapeutics (SABS)
Evercore ISI Analyst forecast on DE:82W
Evercore ISI
Evercore ISI
€20.8
Hold
-15.73%
Downside
Reiterated
05/12/26
Evercore ISI Sticks to Its Hold Rating for Hims & Hers Health (HIMS)
Jefferies
€22.1€21.23
Hold
-13.98%
Downside
Reiterated
05/12/26
Hims & Hers price target lowered to $24.50 from $25.50 at JefferiesHims & Hers price target lowered to $24.50 from $25.50 at Jefferies
Morgan Stanley Analyst forecast on DE:82W
Morgan Stanley
Morgan Stanley
€18.2
Hold
-26.26%
Downside
Assigned
05/12/26
Hims & Hers Health: Hold Maintained as Profitability Pressures Offset Growth; $21 Price Target Reiterated
TD Cowen Analyst forecast on DE:82W
TD Cowen
TD Cowen
€19.93€21.66
Hold
-12.22%
Downside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Harrow Health (NASDAQ: HROW), Hims & Hers Health (NYSE: HIMS) and ArriVent BioPharma, Inc. (NASDAQ: AVBP)
Citi
€20.8€24.26
Hold
-1.69%
Downside
Assigned
05/12/26
Hims & Hers price target raised to $28 from $24 at CitiHims & Hers price target raised to $28 from $24 at Citi
J.P. Morgan Analyst forecast on DE:82W
J.P. Morgan
J.P. Morgan
€30.33€28.6
Buy
15.87%
Upside
Reiterated
05/12/26
Hims & Hers price target lowered to $33 from $35 at JPMorganHims & Hers price target lowered to $33 from $35 at JPMorgan
Needham
€30.33
Buy
22.89%
Upside
Reiterated
05/12/26
Analyst Reaffirms Buy on Hims & Hers, Lifts Price Target to $35 on Long-Term Growth from Novo Partnership
Deutsche Bank  Analyst forecast on DE:82W
Deutsche Bank
Deutsche Bank
€24.26€21.66
Hold
-12.22%
Downside
Assigned
05/05/26
Hims & Hers price target lowered to $25 from $28 at Deutsche BankHims & Hers price target lowered to $25 from $28 at Deutsche Bank
Leerink Partners Analyst forecast on DE:82W
Leerink Partners
Leerink Partners
Hold
Reiterated
04/16/26
Push to ease peptide restrictions positive for Hims & Hers, says Leerink Push to ease peptide restrictions positive for Hims & Hers, says Leerink
Nephron Analyst forecast on DE:82W
Unknown Analyst
Nephron
Not Ranked
Nephron
€30.33
Buy
22.89%
Upside
Upgraded
03/09/26
Hims & Hers upgraded to Buy from Hold at Nephron ResearchHims & Hers upgraded to Buy from Hold at Nephron Research
BTIG
Hold
Reiterated
03/05/26
Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hims & Hers Health

3 Months
Maria RippsCanaccord Genuity
Success Rate
10/14 ratings generated profit
71%
Average Return
+25.86%
Copying Maria Ripps's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +25.86% per trade.
1 Year
Success Rate
8/10 ratings generated profit
80%
Average Return
+34.84%
Copying Glen Santangelo's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +34.84% per trade.
2 Years
Success Rate
8/10 ratings generated profit
80%
Average Return
+35.98%
Copying Glen Santangelo's trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +35.98% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

82W Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
6
7
7
1
0
Buy
1
4
5
10
7
Hold
20
31
36
32
21
Sell
12
9
6
0
0
Strong Sell
0
0
0
0
0
total
39
51
54
43
28
In the current month, 82W has received 7 Buy Ratings, 21 Hold Ratings, and 0 Sell Ratings. 82W average Analyst price target in the past 3 months is 23.75.
Each month's total comprises the sum of three months' worth of ratings.

82W Financial Forecast

82W Earnings Forecast

Next quarter’s earnings estimate for 82W is -€0.04 with a range of -€0.14 to €0.08. The previous quarter’s EPS was -€0.34. 82W beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 82W has Performed in-line its overall industry.
Next quarter’s earnings estimate for 82W is -€0.04 with a range of -€0.14 to €0.08. The previous quarter’s EPS was -€0.34. 82W beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 82W has Performed in-line its overall industry.

82W Sales Forecast

Next quarter’s sales forecast for 82W is €595.44M with a range of €585.94M to €630.87M. The previous quarter’s sales results were €523.51M. 82W beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 82W has Performed in-line its overall industry.
Next quarter’s sales forecast for 82W is €595.44M with a range of €585.94M to €630.87M. The previous quarter’s sales results were €523.51M. 82W beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 82W has Performed in-line its overall industry.

82W Stock Forecast FAQ

What is DE:82W’s average 12-month price target, according to analysts?
Based on analyst ratings, Hims & Hers Health, Inc.’s 12-month average price target is 23.75.
    What is DE:82W’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for DE:82W, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Hims & Hers Health, Inc. a Buy, Sell or Hold?
        Hims & Hers Health, Inc. has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 9 hold ratings and 0 sell ratings.
          What is Hims & Hers Health, Inc.’s share price target?
          The average share price target for Hims & Hers Health, Inc. is 23.75. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is €30.33 ,and the lowest forecast is €18.20. The average share price target represents -3.76% Decrease from the current price of €24.68.
            What do analysts say about Hims & Hers Health, Inc.?
            Hims & Hers Health, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
              How can I buy shares of Hims & Hers Health, Inc.?
              To buy shares of DE:82W, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.